NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers, the Trump administration said Tuesday.

The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and Trulicity.

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.

Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into effect until 2028.

The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz.

The CMS has proposed several key changes for 2027, to make sure Medicare "works better for the people it serves."

GoodRx reports five major changes to Medicare in 2026, including a $2,100 Part D out-of-pocket limit, prior authorization for some services, and auto-renewal for payment plans.